Answer:
https://www.you tube.com/watch?v=RCjNN6JfSmE
This video gives stretches for the soleus muscle.
It's titled Soleus Stretch - Ask Doctor Jo, if you don't trust the link I answered. (Which I would get, I usually don't trust links from complete strangers on the internet).
Explanation:
Answer:
yes that's correct but what are we answering then?
Explanation:
Answer:
Drug-drug interactions (DDIs) are one of the commonest causes of medication error in developed countries, particularly in the elderly due to poly-therapy, with a prevalence of 20-40%. In particular, poly-therapy increases the complexity of therapeutic management and thereby the risk of clinically important DDIs, which can both induce the development of adverse drug reactions or reduce the clinical efficacy. DDIs can be classify into two main groups: pharmacokinetic and pharmacodynamic. In this review, using Medline, PubMed, Embase, Cochrane library and Reference lists we searched articles published until June 30 2012, and we described the mechanism of pharmacokinetic DDIs focusing the interest on their clinical implications.
Keywords: Absorption, adverse drug reaction, distribution, drug-drug interactions, excretion, metabolism, poly-therapy
Answer:
Here are the duties of a pharmacy technician in a hospital
Compounding intravenous (IV) solutions.
Delivering medications to and from satellite pharmacies.
Restocking automated medication dispensing systems.
Mixing and dispensing orally-administered medications.
Unit-dosing tablets from a bulk bottle.
Hope this helps, have a great day/night, stay safe, and happy thanksgiving!
Answer:
b) blastic red blood cell (RBC).
Explanation:
In excess of 340 blood group antigens have now been described that vary between individuals. Thus, any unit of blood that is nonautologous represents a significant dose of alloantigen. Most blood group antigens are proteins, which differ by a single amino acid between donors and recipients. Approximately 1 out of every 70 individuals are transfused each year (in the United States alone), which leads to antibody responses to red blood cell <u>(RBC) alloantigens</u> in some transfusion recipients. When alloantibodies are formed, in many cases, RBCs expressing the antigen in question can no longer be safely transfused. However, despite chronic transfusion, only 3% to 10% of recipients (in general) mount an alloantibody response. In some disease states, rates of alloimmunization are much higher (eg, sickle cell disease). For patients who become alloimmunized to multiple antigens, ongoing transfusion therapy becomes increasingly difficult or, in some cases, impossible. While alloantibodies are the ultimate immune effector of humoral alloimmunization, the cellular underpinnings of the immune system that lead to ultimate alloantibody production are complex, including antigen consumption, antigen processing, antigen presentation, T-cell biology.
